Delving into the Latest Updates on TrippBio, Inc. with Synapse

A Single Dose Oral Bioavailability Study of PanCytoVir™ Oral Suspension (100 mg/ml) 1000 mg Versus Probenecid 500 mg Tablets, 1000 mg (2 X 500 mg) in Healthy, Adult, Human Subjects Under Fasting Conditions

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover, single dose oral relative bioavailability study of a novel PanCytoVir™ oral suspension (100 mg/mL) versus probenecid 500 mg tablets in normal healthy, adult, human subjects under fasting conditions.

开始日期2024-09-01

申办/合作机构

TrippBio, Inc.

NCT06025318 / Completed临床1期

An Open-label, Balanced, Randomized, Two-period, Crossover, Single Dose Study to Compare the Bioavailability of PanCytoVir™ Oral Suspension (100mg/ml), in Healthy, Adult, Human Subjects Under Fed and Fasting Conditions

This is an open-label, balanced, randomized, two-period, crossover, single dose study to compare the relative bioavailability in normal healthy, adult, human subjects under Fed and Fasting conditions. Subjects will receive a single oral dose of probenecid oral suspension (100 mg/mL) under fed and fasted conditions.

开始日期2024-09-01

申办/合作机构

TrippBio, Inc.

NCT05442983 / Completed临床2期

A Randomized, Single-center, Single-blind, Placebo-controlled Study to Evaluate the Efficacy of PanCytoVir™ 500 mg Twice Daily and 1000 mg Twice Daily for the Treatment of Non-hospitalized Patients With COVID-19 Infection

This is a randomized, single-center, single-blind, placebo controlled, study to evaluate efficacy of PanCytoVir™ 500 mg twice daily and 1000 mg twice daily for the treatment of non-hospitalized patients with COVID-19 infection.

开始日期2022-07-12

申办/合作机构

TrippBio, Inc.

100 项与 TrippBio, Inc. 相关的临床结果

登录后查看更多信息

0 项与 TrippBio, Inc. 相关的专利（医药）

登录后查看更多信息

9

项与 TrippBio, Inc. 相关的文献（医药）

Viruses

Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19

Article

作者: Martin, David E ; Tripp, Ralph A

In the early stages of drug discovery, researchers develop assays that are compatible with high throughput screening (HTS) and structure activity relationship (SAR) measurements. These assays are designed to evaluate the effectiveness of new and known molecular entities, typically targeting specific features within the virus. Drugs that inhibit virus replication by inhibiting a host gene or pathway are often missed because the goal is to identify active antiviral agents against known viral targets. Screening efforts should be sufficiently robust to identify all potential targets regardless of the antiviral mechanism to avoid misleading conclusions.

Scientific reports

Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

Article

作者: Blahunka, Kathy ; Balyan, Rajiv ; Murray, Jackelyn ; Tripp, Ralph A ; Hogan, Robert J ; Sancilio, Fred D ; Martin, David E ; Lovern, Mark ; Still, Richard

Abstract:

Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.

Viruses

Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice

Article

作者: Murray, Jackelyn ; Martin, David E. ; Hosking, Sarah ; Orr-Burks, Nichole ; Tripp, Ralph A. ; Hogan, Robert J.

Avian influenza (AI) viruses cause infection in birds and humans. Several H5N1 and H7N9 variants are highly pathogenic avian influenza (HPAI) viruses. H5N1 is a highly infectious bird virus infecting primarily poultry, but unlike other AIs, H5N1 also infects mammals and transmits to humans with a case fatality rate above 40%. Similarly, H7N9 can infect humans, with a case fatality rate of over 40%. Since 1996, there have been several HPAI outbreaks affecting humans, emphasizing the need for safe and effective antivirals. We show that probenecid potently inhibits H5N1 and H7N9 replication in prophylactically or therapeutically treated A549 cells and normal human broncho-epithelial (NHBE) cells, and H5N1 replication in VeroE6 cells and mice.

1

项与 TrippBio, Inc. 相关的新闻（医药）

2023-08-01

·drugs

Oral Probenecid Cuts Time to Viral Clearance in COVID-19

TUESDAY, Aug. 1, 2023 -- For patients with symptomatic, mild-to-moderate COVID-19, oral probenecid results in a reduction in the time to viral clearance, according to a study published online July 6 in Viruses . David E. Martin, Pharm.D., from TrippBio Inc. in Jacksonville, Florida, and colleagues conducted a phase 2 randomized, dose range-finding trial in nonhospitalized patients with symptomatic, mild-to-moderate COVID-19. Patients were randomly assigned to 500 mg probenecid, 1,000 mg probenecid, or placebo every 12 hours for five days (25 patients in each group). The researchers found that the median time to viral clearance was significantly shorter for probenecid 1,000 mg and for probenecid 500 mg versus placebo (seven and nine days, respectively, versus 11 days). Furthermore, the median time to viral clearance was significantly shorter for probenecid 1,000 versus 500 mg (seven versus nine days). On days 3 and 5, all patients reported at least one COVID-19-related symptom; however, on day 10, complete resolution of symptoms was reported by a significantly greater proportion of patients receiving probenecid 1,000 mg and probenecid 500 mg versus placebo (68 and 56 percent, respectively, versus 20 percent). The incidence of adverse events during treatment was 12 percent and was similar across all groups; all events were mild, with no reports of serious events or discontinuation due to an adverse event. "Based on these results, probenecid 1,000 mg b.i.d. for five days will be further evaluated to characterize its efficacy in patients with COVID-19," the authors write. Several authors disclosed ties to TrippBio, which funded the study; one author is employed by Zenovel Pharma Services; one author is an inventor on a granted patent application covering the method of use of probenecid as a treatment for coronavirus infections. Abstract/Full Text (subscription or payment may be required) Posted August 2023 Further Support and Information on COVID-19 COVID-19: Prevention & Investigational Treatments COVID-19 Support Group Coronavirus Disease Guide

临床2期临床结果

100 项与 TrippBio, Inc. 相关的药物交易

登录后查看更多信息

100 项与 TrippBio, Inc. 相关的转化医学

登录后查看更多信息